Medical technology provider HeartBeam, Inc. (NASDAQ:BEAT) received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its at-home cardiac assessment tool.
The federal regulatory agency granted the HeartBeam System a special expedited designation, recognizing its potential to help doctors identify heart attacks remotely when symptoms first emerge.
• HeartBeam stock is surging to new heights today. Why are BEAT shares rallying?
Expedited Regulatory Review
The federal agency approved the company’s request in less than 30 days, moving much faster than the standard 60-day statutory review window.
By securing this status, the medical technology firm gains prioritized interactions and expedited reviews with regulators.
The company will collaborate closely with federal reviewers to map out the clinical and regulatory steps required for potential market clearance, ensuring an efficient path through the development phase.
Paving the Way for Medicare Coverage
This regulatory milestone also opens the door for faster Medicare reimbursement.
Federal health agencies recently proposed a pathway that could allow eligible medical devices to receive a national coverage determination on the exact day they secure regulatory clearance.
Additionally, the medical firm applied for enrollment in another federal advisory program covering the total product life cycle.
See More: Top Momentum Stocks
Clinical Data and Next Steps
Recent clinical presentations, including proof-of-concept data from a 2025 American Heart Association scientific session and a 134-patient pilot study, supported the agency’s swift decision.
The system utilizes 3D ECG technology to capture the heart’s electrical signals from three non-coplanar dimensions, allowing physicians to detect myocardial infarctions the moment symptoms appear, regardless of the patient’s location.
Looking ahead, the enterprise plans to coordinate with regulators to design a comprehensive, multicenter pivotal study in the upcoming months.
The organization expects to begin patient enrollment shortly afterward, aiming to expand the device’s official indications to include formal heart attack assessments.
If successful, this study will support the final submission for the expanded use case.
BEAT Price Action: HeartBeam shares were up 62.43% to 71 cents at the time of publication on Monday, according to Benzinga Pro data.
Photo via Shutterstock